ABSTRACT
Background: This study evaluated the effects of zein nanoparticles with resveratrol on neuroinflammation caused by Alzheimer's disease. Method: The sample consisted of 30 animals divided into control (C), positive control (CP), white nanoparticles (NB), resveratrol nanoparticles (NR) and resveratrol (R) groups. The animals received 10 mg/kg of resveratrol or nanoparticles according to the group, daily, for 15 days, oral administration. Afterward, they were submitted to immunohistochemical (IHC) analyses. Results: the IHC showed that there was no change in the morphological brain composition in the NR and C groups. Conversely, in the CP, NB, and R groups, changes in the deposition of Anti Tau were observed. The NR group showed a normal projection of taurine in the axon, which was not presented in the same way in the other groups. The CD68 marker showed no microglial activation in the R and C groups. Quantitative analyses of Anti Beta-Amyloid in the NR group showed a statistical difference com-pared to the CP, NB, and R groups, whereas the Anti Tau analysis showed a significant difference between the CP and NR groups. The CD68 marker showed a significant difference between the C and NR groups. The analysis of cy-tokines showed a significant difference in TNF-α between the C and CP groups, C and NB groups, CP and NR groups, and NB and NR groups. IL-6 and InF-δ showed no significant difference between all groups. IL-10 showed significant differences between the C and NR groups, C and R groups, and CP and NR groups. Conclusion: NR prevented the evolution of neuroinflammation(AU).
Introdução: Este estudo avaliou os efeitos das nanopartículas de zeína com resveratrol na neuroinflamação causada pela doença de Alzheimer. Método: A amostra consistiu em 30 animais divididos em grupos de controle (C), controle positivo (CP), nanopartículas brancas (NB), nanopartículas de resveratrol (NR) e resveratrol (R). Os animais receberam 10 mg/kg de resveratrol ou nanopartículas de acordo com o grupo, diariamente, por 15 dias, por via oral. Em seguida, foram submetidos a análises imuno-histoquímicas (IHC). Resultados: A IHC mostrou que não houve alteração na composição morfológica do cérebro nos grupos NR e C. Por outro lado, nos grupos CP, NB e R, foram observadas alterações na deposição de Anti Tau. O grupo NR mostrou uma projeção normal de taurina no axônio, que não se apresentou da mesma forma nos outros grupos. O marcador CD68 não mostrou ativação microglial nos grupos R e C. As análises quantitativas do antibeta-amiloide no grupo NR mostraram uma diferença estatística quando comparadas aos grupos CP, NB e R, enquanto a análise do antitau mostrou uma diferença significativa entre os grupos CP e NR. O marcador CD68 mostrou uma diferença significativa entre os grupos C e NR. A análise das citocinas mostrou uma diferença significativa no TNF-α entre os grupos C e CP, C e NB, CP e NR, e NB e NR. IL-6 e InF-δ não apresentaram diferença significativa entre todos os grupos. A IL-10 apresentou diferenças significativas entre os grupos C e NR, C e R, e CP e NR. Conclusão: A NR impediu a evolução da neuroinflamação (AU).
Subject(s)
Animals , Nanoparticles , Alzheimer Disease , ResveratrolABSTRACT
Transcranial photobiomodulation is an innovative method for the stimulation of neural activity which consists of the exposure of neural tissue to low-level light irradiance. In the present study, light-emitting diodes (LEDs) were used as light source due to their practicality and low cost. The objective was to analyze the effects of transcranial photobiomodulation using 945-nm LED in university students with anxiety and depression. Sample was composed of 22 individuals (17-25 years of age) divided into 2 groups of 11. LED group was treated with 945-nm LEDs for 1 min and 25 s (9.35 J/cm2), while in the placebo group, the device was off when placed in contact with the frontal bone for the same amount of time as in treatment group. Participants were evaluated at baseline and after 30 days with the hospital anxiety and depression scale (HADS), the faces test, the designs test, and the grip strength test. On the HADS for anxiety, the mean PAB, PAA, PhAB, and PhAA were 13.89 ± 3.55, 12.82 ± 3.18, 10.75 ± 2.49, and 6.66 ± 2.50 points, respectively. In the HADS for depression, the mean for the PDB group was 13.89 ± 3.55 points, in the PhDB group 12.82 ± 3.18 points, in the PDA group 10.75 ± 2.49 points, and in the PhDA group 6.66 ± 2.50 points. In the PA and PD groups, mean values of 8.0 ± 1.5 and 8.9 ± 1.26 scores were obtained, but did not reach significance; however, between PA and PhD analysis, a significance level of p = 0.0003 was obtained. The 945-nm LED transcranial photobiomodulation improves brain activity and may clinically decrease anxiety and depression.
